EU rules for human-derived materials reach pharmaceutical supply chains
Published on 18 November 2026
Drug developers and manufacturers may need to revisit how upstream sourcing safeguards interact with medicines rules
At a glance
For human-derived material used to manufacture medicines, specified SoHO requirements can apply from donor assessment and collection through to release and distribution to the manufacturer.
Where a product is made exclusively for therapeutic use in the person providing the material, the SoHO requirements are limited to testing and collection.
The import-authorisation exception for qualifying plasma does not extend to all pharmaceutical starting materials and does not remove SoHO entity registration.
The SoHO Regulation arrives alongside a far-reaching overhaul of EU pharmaceutical legislation, but addresses a distinct part of the pharmaceutical supply chain. Its significance lies upstream of the medicinal product: in the human-derived material used in its manufacture and the activities through which that material reaches the manufacturer.
From 7 August 2027, specified requirements under Regulation (EU) 2024/1938 on substances of human origin (SoHO) will apply alongside the medicines framework. The regulation's broader scope and activity-based structure mean that the regulatory status of the finished medicine does not, by itself, determine how its human-derived inputs are regulated.
The interaction is relevant to conventional medicines, advanced therapy medicinal products (ATMPs) and investigational medicines. The applicable SoHO requirements vary according to the activities performed and whether the resulting product is intended for the person from whom the material was collected or for someone else. The SoHO Coordination Board's questions and answers in September provided further guidance on where the two frameworks meet.
Two connected frameworks
Where human-derived material is used to manufacture a medicine, the SoHO and pharmaceutical frameworks govern different parts of the same supply chain. The SoHO Regulation applies specified safeguards to the material before it reaches the manufacturer. EU pharmaceutical legislation governs the resulting medicinal product's manufacture and, as applicable, clinical development and authorisation. The SoHO Regulation does not create an alternative route to market for that product.
SoHO requirements cover donor registration and assessment, testing, collection and release. They also apply to storage, distribution, import and export up to and including distribution to the manufacturer. The regulatory allocation therefore turns on the activities performed at each stage, not simply on whether the material will ultimately form part of a medicinal product. This reflects the regulation's wider activity-based approach.
The analysis is not necessarily limited to the ingredient responsible for the medicine's therapeutic effect. The SoHO Coordination Board interprets the manufacturing route as extending to human-derived inputs that are not active ingredients and are not intended to remain in the finished product, because they may still transfer biological risks. Developers may therefore need to consider relevant process inputs as well as the cells, tissue or other human-derived material identified in the product description.
Allogeneic and autologous rules differ
The applicable SoHO requirements depend partly on who will receive the manufactured product.
Where human-derived material is collected to manufacture a product for use in other people, known as an allogeneic process, the broader set of upstream requirements described above applies.
Where the product is made exclusively for therapeutic use in the person from whom the material was collected, known as the autologous use, the SoHO Regulation applies only to the testing and collection activities. The resulting therapy remains subject to the applicable medicines requirements and its collection pathway is therefore narrower in scope rather than unregulated.
Chimeric antigen receptor T-cell therapies, which involve collecting and modifying T cells so that they recognise and attack cancer cells, illustrate the difference. An autologous programme uses a patient's own T cells to manufacture a treatment for that patient, whereas an allogeneic programme uses cells collected from a donor to manufacture treatments for other patients. The two models are treated differently under the SoHO Regulation, so their collection arrangements and allocation of responsibilities should not be assumed to be the same.
The position may also change as a development programme evolves. A sourcing model designed for patient-specific manufacture may not remain appropriate if a company moves towards donor-derived manufacture for several recipients.
Processing of collected material
Human-derived material may undergo processing while it is still held by a collection or storage organisation before transfer to the pharmaceutical manufacturer. According to the SoHO Coordination Board, processing carried out for the manufacture of a medicine is nevertheless governed by the applicable pharmaceutical requirements, even when it is performed by a SoHO entity. Collection, testing, storage and release undertaken by the same organisation may remain subject to the specified SoHO requirements. The applicable framework therefore depends on the particular activity, rather than the operator's identity or the point at which the material physically reaches the manufacturer.
The board illustrates the distinction using cryopreservation: freezing the material is processing, whereas maintaining it in a frozen state is storage. A contractor may perform both activities at the same premises, but its status as a SoHO entity does not establish compliance with the pharmaceutical requirements applicable to the processing step. Contracts and oversight arrangements may therefore need to distinguish between activities that appear operationally connected. The board anticipates coordination between the relevant authorities and notes that the associated good manufacturing practice guidance is under revision.
Upstream manufacturing quality
The suitability of human-derived material for pharmaceutical manufacture can depend on decisions made before it reaches the manufacturer. How the material is collected, tested and documented may affect whether it can be used in the intended manufacturing process. SoHO authorisation of a supplier therefore provides regulatory assurance, but does not establish that every shipment will meet the manufacturer's product-specific requirements.
The European Directorate for the Quality of Medicines and HealthCare (EDQM) sixth-edition Tissues and Cells Guide addresses how manufacturers and suppliers can manage that interface. It recommends agreeing requirements such as cell number, viability and composition before collection, together with how results will be measured, documented and communicated. It also envisages audits by ATMP manufacturers, despite the supplier's SoHO authorisation. These arrangements can reduce the risk of material arriving at the manufacturing site without the characteristics or records needed for its intended use.
The applicable consent or authorisation also needs to cover the proposed use. The regulation requires living donors, or those granting consent on a donor's behalf, to receive information on possible research or commercial uses of the material, including its use to manufacture products governed by other EU legislation. It also requires specific consent for those uses alongside compliance with applicable member state requirements.
Consistent with this, the EDQM guide highlights the need to check the consent where stored material may later be used for another ATMP. Particular care may therefore be needed where stored material is acquired with a cell bank, included in a licensed platform or proposed for another development programme. National rules may add another layer: a pre-existing biobank framework may apply in certain EU jurisdictions to material intended exclusively for scientific research and not for human application. This means that access to the material does not, by itself, establish that it may be used for the proposed programme: the regulatory assessment would need to consider how the material was obtained, the scope of the consent and any applicable national requirements.
Release and third-country sourcing
The distinction between registration, establishment authorisation and preparation authorisation is particularly relevant to pharmaceutical supply chains. Material distributed for manufacture under the relevant route does not require a SoHO preparation authorisation, but the organisations responsible for the upstream activities may still need to be registered or authorised. Where the broader manufacturing route applies, the material must also be released before it is distributed to the manufacturer, confirming that it meets the applicable SoHO quality and safety criteria.
That release is not the same as the qualified person's later certification of a medicinal product batch under EU pharmaceutical law. The two decisions concern different stages of the supply chain and may be taken by different organisations.
Third-country sourcing adds a further layer. An organisation bringing SoHO into the EU before release will generally require authorisation as an importing SoHO establishment and must have a written agreement with the third-country supplier covering the quality, safety and effectiveness of the imported material. A specific regulatory exception applies to human plasma intended for medicines manufacture and included in a plasma master file: importing-establishment authorisation is not required, but registration as a SoHO entity remains necessary.
The limited scope of that exception is notable. In its initial response to the European Commission's proposal, the European Federation of Pharmaceutical Industries and Associations sought a broader exclusion for pharmaceutical imports and exports, reflecting industry concerns about overlapping controls. The final Regulation retains a narrower exception for qualifying plasma.
Downstream exposure remains
The fact that a medicinal product is manufactured from, or incorporates, SoHO does not by itself make the marketing authorisation holder or distributor a SoHO entity. That status depends on whether the business itself carries out a regulated activity involving the underlying material. A company that also carries out donor testing or collects, stores, releases or distributes the underlying material may therefore have direct obligations under the regulation.
The effect of the regulation can extend further downstream. Relevant information about a serious reaction or event must be communicated to manufacturers that received affected material, enabling them to assess the implications after the material has entered manufacturing. In practice, the value of that information will depend on whether the affected input can be traced and the alert reaches the appropriate quality function. These questions sit alongside the wider requirements concerning traceability, safety information and continuity of supply.
Osborne Clarke comment
The SoHO Regulation creates a more nuanced position for pharmaceutical supply chains than either complete exclusion or wholesale application. Mapping the material, its intended use, the activities performed and the operators involved may help clarify where the SoHO and medicines frameworks meet and provide businesses with a sounder basis for agreements with collection organisations and contractors.
Consent documentation may warrant particular attention where a substance of human origin could support several programmes, while a move from patient-specific to donor-derived manufacture may reopen questions of classification and innovation strategy. Where direct obligations sit upstream, evidence of supplier readiness, credible alternatives and a reliable route for safety information may prove more useful than a broad compliance warranty.